Media Image Professor Nick Turner, Genotypes, Phenotypes and Cancer Evolution Theme Lead Our vision to improve patient outcome through precisely defining when, who and how to treat can only be achieved by innovating in molecular diagnostics and analytic techniques. This cross-cutting theme will support our research by developing innovative molecular diagnostic techniques, including in blood-based biomarkers and the monitoring of residual disease, to better understand responses to treatment and cancer evolution. Theme aims To deliver integrated somatic and germline genetic profiling for patients with cancer To integrate liquid biopsies with associated genotyping into routine practice for cancer patients to enhance targeted therapy delivery To focus adjuvant therapy delivery through more exact prognostication of patients with early stage cancer To use the principles of cancer evolution in biomarker development and therapeutic approaches to prevent drug resistance To integrate molecular imaging and radiomics with genotyping and phenotyping Theme lead Professor Nicholas Turner (pictured above): Academic Consultant Clinical Oncologist at The Institute of Cancr Research, London, expertise in breast cancer therapeutic biomarker development, including circulating tumour DNA
Blood will tell Research at The Royal Marsden and the ICR into blood tests known as ‘liquid biopsies’ could represent a major step forward in our ability to detect and monitor breast and other cancers.
